GSK CEO Sees RAPT Therapeutics Acquisition as Template for Future Deals -- Market Talk

Dow Jones

04/29

1039 GMT - GSK CEO Luke Miels says the U.K. pharmaceutical company's future deals could follow the pattern of its recent $2.2 billion acquisition of allergy-drug developer RAPT Therapeutics. The company could target companies working on drugs based on proven science that are developing products with an edge over those already on the market, Miels says in a call with reporters. In future dealmaking, GSK is more likely to focus on areas where it is already commercially active or those adjacent to them, as the barriers to expand into new fields are higher, he adds. GSK agreed to buy RAPT in January, just a few weeks after Miels took over as CEO, and closed the deal in March. Shares fall 2.5%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

April 29, 2026 06:39 ET (10:39 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2631592220"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2631592220\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2631592220?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 18:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631592220","market":"hk","top_or_hot":-1,"title":"GSK CEO Sees RAPT Therapeutics Acquisition as Template for Future Deals -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1039 GMT - GSK CEO Luke Miels says the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. pharmaceutical company's future deals could follow the pattern of its recent $2.2 billion acquisition of allergy-drug developer RAPT <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. The company could target companies working on drugs based on proven science that are developing products with an edge over those already on the market, Miels says in a call with reporters. In future dealmaking, GSK is more likely to focus on areas where it is already commercially active or those adjacent to them, as the barriers to expand into new fields are higher, he adds. GSK agreed to buy RAPT in January, just a few weeks after Miels took over as CEO, and closed the deal in March. Shares fall 2.5%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2026 06:39 ET (10:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK CEO Sees RAPT Therapeutics Acquisition as Template for Future Deals -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK CEO Sees RAPT Therapeutics Acquisition as Template for Future Deals -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-29 18:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1039 GMT - GSK CEO Luke Miels says the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. pharmaceutical company's future deals could follow the pattern of its recent $2.2 billion acquisition of allergy-drug developer RAPT <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. The company could target companies working on drugs based on proven science that are developing products with an edge over those already on the market, Miels says in a call with reporters. In future dealmaking, GSK is more likely to focus on areas where it is already commercially active or those adjacent to them, as the barriers to expand into new fields are higher, he adds. GSK agreed to buy RAPT in January, just a few weeks after Miels took over as CEO, and closed the deal in March. Shares fall 2.5%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2026 06:39 ET (10:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2631592220","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2631592220","pubTimestamp":1777459140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1039 GMT - GSK CEO Luke Miels says the U.K. pharmaceutical company's future deals could follow the pattern of its recent $2.2 billion acquisition of allergy-drug developer RAPT Therapeutics. The company could target companies working on drugs based on proven science that are developing products with an edge over those already on the market, Miels says in a call with reporters. In future dealmaking, GSK is more likely to focus on areas where it is already commercially active or those adjacent to them, as the barriers to expand into new fields are higher, he adds. GSK agreed to buy RAPT in January, just a few weeks after Miels took over as CEO, and closed the deal in March. Shares fall 2.5%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU1829250122.USD":"高盛欧洲核心股票组合Acc","RAPT":"RAPT Therapeutics, Inc.","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","GSK.UK":"葛兰素史克","BK4007":"制药","GSKH":"GSK plc ADRhedged","GSK":"葛兰素史克","BK4588":"碎股"},"translate_title":"葛兰素史克首席执行官将RAPT Therapeutics收购视为未来交易的模板——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1.5,"GSK.UK":0.6,"RAPT":1.5,"GSKH":0.6},"content_text":"1039 GMT - GSK CEO Luke Miels says the U.K. pharmaceutical company's future deals could follow the pattern of its recent $2.2 billion acquisition of allergy-drug developer RAPT Therapeutics. The company could target companies working on drugs based on proven science that are developing products with an edge over those already on the market, Miels says in a call with reporters. In future dealmaking, GSK is more likely to focus on areas where it is already commercially active or those adjacent to them, as the barriers to expand into new fields are higher, he adds. GSK agreed to buy RAPT in January, just a few weeks after Miels took over as CEO, and closed the deal in March. Shares fall 2.5%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2026 06:39 ET (10:39 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}